COMP <GO>
ACLS vs ACMR // EV/EBITDA & P/E VALUATION
Axcelis Technologies Inc. (NASDAQ) VS. ACM Research Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: ACLS 9
— ACMR 2
▲ EV/EBITDA & P/E VALUATION LEADER: ACMR
LAST: $112.02 (-1.50%) • MKT CAP: $3.46B
valuation
25.7x
LAST: $49.29 (-7.03%) • MKT CAP: $3.43B
valuation
18.2x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACLS VS. ACMR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACLS | ACMR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.90% | 44.40% | +0.50 | ACLS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.60% | 9.80% | +0.80 | ACLS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 25.7x | 18.2x | +7.50 | ACMR | /valuation <GO> |
| Free Cash Flow Yield | 3.09% | -1.94% | +5.03 | ACLS | /fcf-yield <GO> |
| Operating Margin | 14.20% | 12.10% | +2.10 | ACLS | /operating-margins <GO> |
| Net Profit Margin | 14.30% | 10.40% | +3.90 | ACLS | /net-margins <GO> |
| Revenue Growth (YoY) | -17.60% | 15.20% | -32.80 | ACMR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.43 | 3.50 | +4.93 | ACLS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.1 | 27.2 | +7.96 | ACLS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.8x | 30.7x | -3.90 | ACLS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.46B | $3.43B | $26.3M | ACLS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACLS REV | ACMR REV | ACLS GROSS % | ACMR GROSS % | ACLS FCF | ACMR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $839.0M | $901.3M | 44.9% | 44.4% | $107.0M | -$66.6M |
| FY 2024 | $1.02B | $782.1M | 44.7% | 50.1% | $128.6M | $70.0M |
| FY 2023 | $1.13B | $557.7M | — | — | $156.9M | -$75.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACLS // BETA —
ACMR // BETA —